Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,032.61 +10.40 (+0.21%) Dow
37,974.57 +221.26 (+0.59%) Nasdaq
15,691.40 +8.03 (+0.05%) Bitcoin USD
63,204.03 +1,199.12 (+1.93%) CMC Crypto 200
885.54 0.00 (0.00%)
Collegium Pharmaceutical, Inc. (COLL)
| Previous close | 35.45 |
| Open | 35.47 |
| Bid | 35.17 x 100 |
| Ask | 35.49 x 100 |
| Day's range | 35.02 - 35.47 |
| 52-week range | 20.83 - 40.95 |
| Volume | |
| Avg. volume | 403,735 |
| Market cap | 1.152B |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | 27.30 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, 2024 (the “Re
- GlobeNewswire
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference being held virtually from April 8-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Wednesday, April 10, 2024, at 3:45
- GlobeNewswire
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical,
